Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

The improved knowledge of pathogenetic mechanisms underlying lymphomagenesis and the discovery of the critical role of tumor microenvironments have enabled the design of new drugs against cell targets and pathways. The Food and Drug Administration (FDA) has approved several monoclonal antibodies (mA...

Descripción completa

Detalles Bibliográficos
Autores principales: Crisci, Stefania, Di Francia, Raffaele, Mele, Sara, Vitale, Pasquale, Ronga, Giuseppina, De Filippi, Rosaria, Berretta, Massimiliano, Rossi, Paola, Pinto, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558009/
https://www.ncbi.nlm.nih.gov/pubmed/31214498
http://dx.doi.org/10.3389/fonc.2019.00443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558009/
https://www.ncbi.nlm.nih.gov/pubmed/31214498
http://dx.doi.org/10.3389/fonc.2019.00443

Ejemplares similares